日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants

一项针对健康受试者的多部分 I 期研究,旨在评估新型甲状腺激素受体β (THR-β) 激动剂 ALG-055009 治疗代谢功能障碍相关性脂肪性肝炎 (MASH) 的安全性、药效学和药代动力学。

Charfi, Hakim; Massetto, Benedetta; Fitzgerald, Megan; Le, Kha; Wang, Stanley; Kan-Eng, Ifong; Venkatraman, Meenakshi; Mohammad, Naqvi; Blatt, Lawrence; Lin, Tse-I; Chanda, Sushmita M; Fry, John

Improving the solubility of pseudo-hydrophobic Alzheimer's Disease medicinal chemicals through co-crystal formulation

通过共晶配方提高伪疏水性阿尔茨海默氏病药物的溶解度

A Tse, I Janilkarn-Urena, J Lin, X Chang, C Efthymiou, A Idrissova, M Zhang, C K Williams, S Magaki, H V Vinters, D L Davies, T Gonen, H J Gukasyan, P M Seidler

Early Detection of Cancer: Evaluation of MR Imaging Grading Systems in Patients with Suspected Nasopharyngeal Carcinoma

癌症早期检测:疑似鼻咽癌患者的磁共振成像分级系统评估

King, A D; Woo, J K S; Ai, Q-Y; Mo, F K F; So, T Y; Lam, W K J; Tse, I O L; Vlantis, A C; Yip, K W N; Hui, E P; Ma, B B Y; Chiu, R W K; Chan, A T C; Lo, Y M D; Chan, K C A

Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)

甲状腺激素受体β激动剂对基因转录的调控在治疗非酒精性脂肪性肝炎(NASH)的临床开发中

Xuan G Luong, Sarah K Stevens, Andreas Jekle, Tse-I Lin, Kusum Gupta, Dinah Misner, Sushmita Chanda, Sucheta Mukherjee, Caroline Williams, Antitsa Stoycheva, Lawrence M Blatt, Leonid N Beigelman, Julian A Symons, Pierre Raboisson, David McGowan, Koen Vandyck, Jerome Deval

Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors

抗病毒抑制与丙型肝炎蛋白酶和聚合酶抑制剂对 RIG-I 信号的恢复

Yuqiong Liang, Hisashi Ishida, Oliver Lenz, Tse-I Lin, Origène Nyanguile, Kenny Simmen, Richard B Pyles, Nigel Bourne, Minkyung Yi, Kui Li, Stanley M Lemon